On May 8, 2024, Sailaja Puttagunta M.D. notified Iterum Therapeutics plc of her decision to resign as Chief Medical Officer the Company, effective May 31, 2024. Dr. Puttagunta?s resignation is due to personal reasons and not a result of any disagreement with the Company. Dr. Puttagunta has agreed to work with the Company as a consultant, on terms yet to be determined, throughout the regulatory review period of the Company?s recently resubmitted new drug application for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women Steven Aronin, M.D., the Company?s current Senior Vice President and Head of Clinical Development, will lead the Company?s development and regulatory activities following the effective date of Dr. Puttagunta?s resignation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.35 USD | -2.88% | -4.26% | -31.47% |
13/05 | Transcript : Iterum Therapeutics plc, Q1 2024 Earnings Call, May 13, 2024 | |
13/05 | Iterum Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.47% | 2.23Cr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+45.66% | 4.07TCr | |
-10.72% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Iterum Therapeutics plc Announces Executive Changes